Drug Name: Vivjoa Active Ingredient: oteseconazole Indications: To reduce the incidence of recurrent vulvovaginal candidiasis (RVVC) in females with a history of RVVC who are not of reproductive potential Approval…
Drug Name: Pluvicto Active Ingredient: lutetium (177Lu) vipivotide tetraxetan Indications: To treat prostate-specific membrane antigen-positive metastatic castration-resistant prostate cancer following other therapies Approval Date: 3/23/2022 Company: Advanced Accelerator Applications USA,…
Drug Approval Name: Ztalmy Indications: To treat seizures in cyclin-dependent kinase-like 5 deficiency disorder Active Ingredient: ganaxolone Company: Marinus Pharmaceuticals, Inc. Approval Date: 3/18/2022 Learn more: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215904s000lbl.pdf
Drug Name: Opdualag Active Ingredient: nivolumab and relatlimab-rmbw Indications: To treat unresectable or metastatic melanoma Approval Date: 3/18/2022 Company: Bristol-Myers Squibb Company Learn more: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761234s000lbl.pdf
Drug Name: Vonjo Indications: To treat intermediate or high-risk primary or secondary myelofibrosis in adults with low platelets. Active Ingredient: Company: CTI BioPharma Corp. Approval Date: 2/28/2022 Learn more: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/208712s000lbl.pdf
Drug Approval Name: Pyrukynd Indications: To treat hemolytic anemia in pyruvate kinase deficiency. Active Ingredient: Mitapivat Company: Agios Pharmaceuticals Inc Approval Date: 2/17/2022 Learn more: https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshot-pyrukynd
Drug Name: Enjaymo Indications: To decrease the need for red blood cell transfusion due to hemolysis in cold agglutinin disease. Active Ingredient: Sutimlimab-jome Company: Bioverativ USA Inc (a Sanofi company)…
Drug Name: Vabysmo Indications: To treat neovascular (wet) aged-related macular degeneration and diabetic macular edema. Active Ingredient: Faricimab-svoa Company: Genentech, Inc Approval Date: 1/28/2022 More Details: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761235s000lbl.pdf
Drug Name: Kimmtrak Indications: To treat unresectable or metastatic uveal melanoma. Active Ingredient: Tebentafusp-tebn Company: Immunocore Commercial LLC Approval Date: 1/25/2022 More Details: https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-kimmtrak
Drug Name: Cibinqo Indications: To treat refractory, moderate-to-severe atopic dermatitis. Cibinqo is a Janus Kinase (JAK) inhibitor that is indicated for the treatment of adults with refractory, moderate-to-severe atopic dermatitis…